A review of the safety, efficacy, and administration of hedgehog inhibitors for the treatment of advanced basal cell carcinoma: An expert consensus panel
Sonidegib and vismodegib have similar efficacy in treating advanced BCC, but sonidegib has lower rates and a greater delay in onset of AEs. Sonidegib has a significantly greater volume of distribution and half-life than those of vismodegib. Dosing interruptions have not been shown to reduce the efficacy of HHIs, and L-carnitine supplementation can help reduce the incidence of muscle spasms.
Authors
- Mohammed Dany (ORCID: https://orcid.org/0000-0002-7060-5385)
- Todd Schlesinger (ORCID: https://orcid.org/0000-0002-1128-9626)
- GEORGE H. MONKS
- Michael B. Mortazie
- Mark Lebwohl (ORCID: https://orcid.org/0000-0002-4705-5303)
- Shannon C. Trotter
- Joshua Burshtein (ORCID: https://orcid.org/0000-0002-9851-088X)
- Scott M. Dinehart (ORCID: https://orcid.org/0000-0002-6147-9604)
- Danny Zakria (ORCID: https://orcid.org/0000-0001-8399-5311)
- Darrell S. Rigel (ORCID: https://orcid.org/0000-0002-4005-7031)
- Milaan Shah (ORCID: https://orcid.org/0000-0002-2911-9887)
- Angela Rosenberg
- Jesse M. Lewin
- Lauren DeBusk
Institutions
- Medical University of South Carolina (US)
- Virginia Commonwealth University (US)
- George Washington University (US)
- Oklahoma City University (US)
- South Carolina Historical Society (US)
- University of Illinois Chicago (US)
- University of Chicago (US)
- Arkansas Cardiology (US)
- Ohio University (US)
- Bennett Aerospace (United States) (US)
- New York University (US)
- The University of Texas Southwestern Medical Center (US)
- University of Oklahoma (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Dermatology Online Journal
- Published
- 2025-09-08
- DOI
- https://doi.org/10.25251/s3cn8t86
- Primary Topic
- Hedgehog Signaling Pathway Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00